financetom
Market
financetom
/
Market
/
HSBC's Tushar Pradhan believes FMCG sector will struggle a bit from hereon, here's why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
HSBC's Tushar Pradhan believes FMCG sector will struggle a bit from hereon, here's why
May 7, 2019 2:21 AM

Tushar Pradhan, the chief investment officer of HSBC Global AMC, spoke to CNBC-TV18 about the fundamentals of the market and shared his views on sectors such as the FMCG and banking.

Share Market Live

NSE

When asked whether there would a re-rating for the financial sector post the fourth-quarter earnings, Pradhan said, "The earnings have been more or less on expected lines. It is difficult to see whether there is going to be re-rating back to the previous levels of valuations because a lot of expectations were build up in terms of growth but most of the banks, NBFCs have curbed their growth expectations. So, there will be time for consolidation before we see any re-rating in the sector going forward".

Talking about the FMCG space, he said, "There has been significant upside to earnings and margins in the last three years. Some of the companies have done exceedingly well and have outperformed the index, as well as the broader set of companies by a very far margin,” said Pradhan, adding that the valuations now has gone through the roof.

“I would think this is not something which is sustainable and at some point of time there will be a return to mean in terms of average margins,” said Pradhan.

"The FMCG space will struggle a bit from hereon and since valuations are not on their side, space does not look very attractive," said Pradhan.

According to him, "The action needs to shift to spaces like cement, infrastructure and it is a good time to build portfolios with them. Currently, the numbers do not suggest that it is an attractive space to look at but if one believes that the economy is going to turnaround then these sectors will do well in spite of a lot of challenges."

First Published:May 7, 2019 11:21 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Gold Moves Higher as U.S. Inflation Report Matches Expectations
Update: Gold Moves Higher as U.S. Inflation Report Matches Expectations
Dec 11, 2024
02:00 PM EST, 12/11/2024 (MT Newswires) -- (Updates prices.) Gold futures rose for a fourth-straight day early on Wednesday as a key U.S. inflation measure met expectations, increasing the likelihood the Federal Reserve will cut interest rates next week. Gold for February delivery was last seen up US$37.80 to US$2,756.20 per ounce. Gold is back in 'Santa' rally territory, currently...
US STOCKS-Wall Street rallies on tame US inflation, Nasdaq jumps above 20,000
US STOCKS-Wall Street rallies on tame US inflation, Nasdaq jumps above 20,000
Dec 11, 2024
* S&P 500, Nasdaq gain; Dow drops * Tesla shares hit record high * Healthcare stocks tank after bipartisan bill * Dow dips 0.01%, S&P 500 up 0.86%, Nasdaq up 1.74% (Updates to 2:20 PM ET) By Chibuike Oguh, Purvi Agarwal and Shashwat Chauhan NEW YORK, Dec 11 (Reuters) - Wall Street stocks jumped on Wednesday as a rally in...
Sector Update: Energy
Sector Update: Energy
Dec 11, 2024
03:16 PM EST, 12/11/2024 (MT Newswires) -- Energy stocks were higher late Wednesday afternoon, with the NYSE Energy Sector Index adding 0.6% and the Energy Select Sector SPDR Fund (XLE) up 0.5%. The Philadelphia Oil Service Sector index climbed 2.7%, while the Dow Jones US Utilities index shed 0.6%. US crude oil stocks, including those in the Strategic Petroleum Reserve,...
Top Midday Decliners
Top Midday Decliners
Dec 11, 2024
02:00 PM EST, 12/11/2024 (MT Newswires) -- Q32 Bio ( QTTB ) said late Tuesday its phase 2a clinical trial in atopic dermatitis failed to meet the primary endpoint in Part B after demonstrating promising findings in Part A. Wells Fargo downgraded the company's shares to equal-weight from overweight while adjusting the stock's price target to $16 from $95. Shares...
Copyright 2023-2026 - www.financetom.com All Rights Reserved